Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
Elif Kadife, Emily Chan, Rodney Luwor, George Kannourakis, Jock Findlay, Nuzhat Ahmed
CANCERS | MDPI | Published : 2019
Approximately seventy percent of ovarian cancer patients succumb to the disease within the first 5 years of diagnosis, even after successful surgery and effective chemotherapy treatment. A small subset of chemotherapy resistant cancer stem cells (CSCs) cause relapse of ovarian cancers. This study investigated the association between paclitaxel-mediated Src activation (p-Src) and CSC populations in driving ovarian cancer progression. We demonstrate that patients with high-stage serous ovarian carcinomas have significantly elevated levels of p-Src, compared to patient with low-stage and benign ovarian tumours. Additionally, p-Src was significantly enhanced in ascites-derived tumour cells obtai..View full abstract
EC was a recipient of the Australian Postgraduate Award. This work was supported by the John Turner Cancer Research Funds to Fiona Elsey Cancer Research Institute, Ballarat, Australia. RL is supported by Victorian Cancer Agency. This work was made possible through the Victorian State Government Operational Infrastructure Support to the Hudson Institute of Medical Research.